Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS [1]

ABSTRACT: PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS [1]

PROVIDER: PRJNA912588 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22746374.fastq.gz	Fastqsanger.gz
	SRR22746375.fastq.gz	Fastqsanger.gz
	SRR22746376.fastq.gz	Fastqsanger.gz
	SRR22746377.fastq.gz	Fastqsanger.gz
	SRR22746378.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS

Project description:PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS

| PRJNA912584 | ENA

PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS [2]

Project description:PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS [2]

| PRJNA912589 | ENA

PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS [2]

Project description:RNA sequencing analysis of human iPSC-derived motor neurons generated from two C9ORF72 ALS/FTD patient lines, treated with negative control ASO (NC ASO) or PIKFYVE ASO. The goal of this study is to evaluate the effect of PIKFYVE suppression in rescuing ALS motor neuron degeneration.

2022-12-18 | GSE221016 | GEO

PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS [1]

Project description:RNA sequencing analysis of human iPSC-derived motor neurons generated from one C9ORF72 ALS/FTD patient line, treated with DMSO or Apilimod. The goal of this study is to evaluate the effect of PIKFYVE inhibitor in rescuing ALS motor neuron degeneration.

2022-12-18 | GSE221015 | GEO

SYF2 Suppression Mitigates Neurodegeneration in Models of Diverse Forms of ALS

Project description:SYF2 Suppression Mitigates Neurodegeneration in Models of Diverse Forms of ALS

| PRJNA902285 | ENA

PIKFYVE inhibition mitigates disease in models of diverse forms of ALS.

Project description:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that results from many diverse genetic causes. Although therapeutics specifically targeting known causal mutations may rescue individual types of ALS, these approaches cannot treat most cases since they have unknown genetic etiology. Thus, there is a pressing need for therapeutic strategies that rescue multiple forms of ALS. Here, we show that pharmacological inhibition of PIKFYVE kinase activates an unconventional protein clearance mechanism involving exocytosis of aggregation-prone proteins. Reducing PIKFYVE activity ameliorates ALS pathology and extends survival of animal models and patient-derived motor neurons representing diverse forms of ALS including C9ORF72, TARDBP, FUS, and sporadic. These findings highlight a potential approach for mitigating ALS pathogenesis that does not require stimulating macroautophagy or the ubiquitin-proteosome system.

| S-EPMC10062012 | biostudies-literature

PIKFYVE Inhibition Mitigates Disease in Models of Diverse Forms of ALS

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-12-18 | GSE221017 | GEO

SYF2 Suppression Mitigates Neurodegeneration in Models of Diverse Forms of ALS

Project description:RNA sequencing analysis of human induced motor neurons generated from a C9ORF72 ALS patient line and its isogenic control, treated with siRNA targetting SYF2. The goal of this study is to evaluate the process of SYF2 suppression in rescuing ALS motor neuron degeneration.

2022-11-23 | GSE218079 | GEO

SYF2 suppression mitigates neurodegeneration in models of diverse forms of ALS.

Project description:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by many diverse genetic etiologies. Although therapeutics that specifically target causal mutations may rescue individual types of ALS, such approaches cannot treat most patients since they have unknown genetic etiology. Thus, there is a critical need for therapeutic strategies that rescue multiple forms of ALS. Here, we combine phenotypic chemical screening on a diverse cohort of ALS patient-derived neurons with bioinformatic analysis of large chemical and genetic perturbational datasets to identify broadly effective genetic targets for ALS. We show that suppressing the gene-encoding, spliceosome-associated factor SYF2 alleviates TDP-43 aggregation and mislocalization, improves TDP-43 activity, and rescues C9ORF72 and causes sporadic ALS neuron survival. Moreover, Syf2 suppression ameliorates neurodegeneration, neuromuscular junction loss, and motor dysfunction in TDP-43 mice. Thus, suppression of spliceosome-associated factors such as SYF2 may be a broadly effective therapeutic approach for ALS.

| S-EPMC10062011 | biostudies-literature

The Motor Neuron m6A Repertoire Governs Neuronal Homeostasis and Augmented m6A Production Mitigates ALS Symptom Manifestation [snMultiome-seq]

Project description:Amyotrophic lateral sclerosis (ALS) is a swiftly progressive and fatal neurodegenerative ailment marked by the degenerative motor neurons (MNs). Why MNs are specifically susceptible in predominantly sporadic cases remains enigmatic. Here, we demonstrated N6-methyladenosine (m6A), an RNA modification catalyzed by the METTL3/METTL14 methyltransferase complex, as a pivotal contributor to ALS pathogenesis. By conditional knockout Mettl14 in murine MNs, we recapitulate almost the full spectrum of ALS disease characteristics. Mechanistically, pervasive m6A hypomethylation triggers dysregulated expression of high-risk genes associated with ALS and an unforeseen reduction of chromatin accessibility in MNs. Additionally, we observed diminished m6A levels in induced pluripotent stem cell (iPSC)-derived MNs from familial and sporadic ALS patients. Restoring m6A equilibrium via a small molecule or gene therapy significantly preserves MNs from degeneration and mitigates motor impairments in ALS iPSC-derived MNs and murine models. Our study presents a substantial stride towards identifying pioneering efficacious ALS therapies via RNA modifications.

2025-04-30 | GSE290242 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data